Paul Feuerstadt, MD, FACG, AGAF
DownloadHi-Res Photo
About
Biography
A native of Long Island, New York, Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude.
Following completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, New York for his clinical fellowship training.
Throughout Dr. Feuerstadt’s training and practice he has been actively involved in research and other academic pursuits. His areas of interest include chronic diarrheal syndromes with a specific focus on Clostridiodes difficile infection, irritable bowel syndrome (IBS) and ischemic diseases of the gut. He has presented his research extensively at national meetings and has authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt’s is teaching, frequently giving lectures locally, regionally and nationally. Dr. Feuerstadt founded a website entitled "Everythingcdifficile.com" as an educational resource for patients and providers about this infectious disease. Finally, he is passionate about mentoring the fellows in the Division of Digestive Disease at Yale-New Haven Hospital where he holds a clinical appointment as an Assistant Clinical Professor of Medicine.
His clinical practice is his ultimate passion filling the majority of his work time as he sees a broad spectrum of patients with gastrointestinal and hepatic disease. Dr. Feuerstadt is affiliated with the St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital, and Milford Hospital.
Appointments
Digestive Diseases
Associate Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Montefiore Medical Center-Albert Einstein College of Medicine (2010)
- Categorical Resident
- New York Presbyterian Hospital-Weill Cornell Medical Center (2007)
- MD
- Weill Cornell Medical College (2004)
- BA
- University of Pennsylvania (2000)
Research
Overview
Medical Research Interests
Epidemiology; Outcome Assessment, Health Care; Treatment Outcome
ORCID
0000-0002-7643-9576
Research at a Glance
Yale Co-Authors
Frequent collaborators of Paul Feuerstadt's published research.
Publications Timeline
A big-picture view of Paul Feuerstadt's research output by year.
Research Interests
Research topics Paul Feuerstadt is interested in exploring.
Abdelkader Chaar, MD, FACP
Rabia Rizwan, MBBS
Kanika Sehgal, MBBS
27Publications
15Citations
Treatment Outcome
Publications
2024
Endoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel
Panel T, Shen B, Abreu M, Cohen E, Farraye F, Fischer M, Feuerstadt P, Kapur S, Ko H, Kochhar G, Liu X, Mahadevan U, McBride D, Navaneethan U, Regueiro M, Ritter T, Sharma P, Lichtenstein G. Endoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel. Gastrointestinal Endoscopy 2024 PMID: 39425706, DOI: 10.1016/j.gie.2024.08.034.Peer-Reviewed Original ResearchAltmetricConceptsInflammatory bowel diseaseInflammatory bowel disease specialistsAssessment of treatment responseBowel diseaseClinical practice patternsConsensus documentMonitoring of disease activityAdult inflammatory bowel diseaseDysplasia surveillancePractice patternsGI pathologistsEndoscopic aspectDisease activityEndoscopic managementPostoperative evaluationConsensus panelTreatment responseInterventional therapyEndoscopic diagnosisIBD managementDiagnosisDiseaseSafety and Tolerability of CP101, a full spectrum, oral microbiome therapeutic for the prevention of recurrent C. difficile infection: A Phase 2 Randomized Controlled Trial.
Allegretti J, Kelly C, Louie T, Fischer M, Hota S, Misra B, Van Hise N, Yen E, Bullock J, Silverman M, Davis I, McGill S, Pardi D, Orenstein R, Grinspan A, El-Nachef N, Feuerstadt P, Borody T, Khanna S, Budree S, Kassam Z. Safety and Tolerability of CP101, a full spectrum, oral microbiome therapeutic for the prevention of recurrent C. difficile infection: A Phase 2 Randomized Controlled Trial. Gastroenterology 2024 PMID: 39366468, DOI: 10.1053/j.gastro.2024.09.030.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCDI recurrenceRecurrent Clostridioides difficile infectionClostridioides difficile infectionGroup compared to placeboStandard-of-careWeek 8Preventing recurrent Clostridioides difficile infectionReduce recurrent Clostridioides difficile infectionSafety profile similar to placeboRecurrent C. difficile infectionIncidence of adverse eventsPlacebo-controlled trialPrevention of recurrent C. difficile infectionPhase 2 randomized controlled trialMicrobiome therapeuticsToxin EIADouble-blindEfficacy endpointPCR-based testsDiagnostic modalitiesOral doseDifficile infectionProportion of participantsAdverse eventsPlaceboA real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States.
Cash B, Lu M, Lembo A, Feuerstadt P, Nguyen L, Terasawa E, Ayyagari R, Du S, Pi S, Westermeyer B, Terreri B, Boules M, Moshiree B. A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States. Journal Of Managed Care & Specialty Pharmacy 2024, 30: 1136-1148. PMID: 39321115, PMCID: PMC11424913, DOI: 10.18553/jmcp.2024.30.10.1136.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsChronic idiopathic constipationHazard ratioIdiopathic constipationTreatment of chronic idiopathic constipationHigher treatment persistencePrescription medicationsComparator medicationUS Food and Drug AdministrationProportion of patientsIBM MarketScan Commercial ClaimsObservational cohort studyFood and Drug AdministrationAdjusted hazard ratiosMarketScan Commercial ClaimsProportion of daysAssociated with lower oddsTreatment persistencePrucaloprideCohort studyOdds ratioPrescription fillsPrescription therapyDrug AdministrationCompare persistenceInclusion criteriaS733 Efficacy, Safety and Time to Response of Linaclotide in Adult Patients With Chronic Idiopathic Constipation: A Post Hoc Subgroup Analysis by Age
Chang L, Brenner D, Chen W, Yerneni N, Wu J, Feuerstadt P, Staller K. S733 Efficacy, Safety and Time to Response of Linaclotide in Adult Patients With Chronic Idiopathic Constipation: A Post Hoc Subgroup Analysis by Age. The American Journal Of Gastroenterology 2024, 119: s503-s504. DOI: 10.14309/01.ajg.0001032300.07115.42.Peer-Reviewed Original ResearchS770 Efficacy and Safety of Linaclotide in Patients With Chronic Idiopathic Constipation: A Post Hoc Analysis of Phase 3 Clinical Study Data Assessing Primary and Additional Endpoints by Race and Ethnicity, and by Age
Moshiree B, Chang L, Boules M, Chen W, Wu J, Li M, Feuerstadt P, Staller K. S770 Efficacy and Safety of Linaclotide in Patients With Chronic Idiopathic Constipation: A Post Hoc Analysis of Phase 3 Clinical Study Data Assessing Primary and Additional Endpoints by Race and Ethnicity, and by Age. The American Journal Of Gastroenterology 2024, 119: s530-s531. DOI: 10.14309/01.ajg.0001032448.76293.ca.Peer-Reviewed Original ResearchThe 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile
Boustany A, Feuerstadt P, Tillotson G. The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile. Advances In Therapy 2024, 41: 3982-3995. PMID: 39276186, PMCID: PMC11480130, DOI: 10.1007/s12325-024-02972-0.Peer-Reviewed Original ResearchAltmetricConceptsIncreased risk of C. difficile infectionRisk of C. difficile infectionClasses of antidepressantsClostridioides difficile infectionNovel treatment optionsPatients' quality of lifeMicrobiome-related factorsDevelopment of dysbiosisOpportunistic infectionsRecurrent CDIGut microbiomeRecurrence rateAntidepressant useDifficile infectionMental disordersTreatment optionsLive biotherapeutic productsComplex pathophysiologyIncreased riskC. difficileGut dysbiosisQuality of lifePatients' qualitySignificant healthcare concernAntidepressantsCorrection to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, Khanna S, Berenson C, Wang E, Cohen S, Korman L, Lee C, Kelly C, Odio A, Cook P, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi D, Hasson B, McGovern B, von Moltke L, Pardi D. Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI. Infectious Diseases And Therapy 2024, 13: 2209-2210. PMID: 39212853, PMCID: PMC11416435, DOI: 10.1007/s40121-024-01036-8.Peer-Reviewed Original ResearchConceptsPUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent Clostridioides difficile infection
Feuerstadt P, Chopra T, Knapple W, Van Hise N, Dubberke E, Baggott B, Guthmueller B, Bancke L, Gamborg M, Steiner T, Van Handel D, Khanna S. PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent Clostridioides difficile infection. Clinical Infectious Diseases 2024, ciae437. PMID: 39180326, DOI: 10.1093/cid/ciae437.Peer-Reviewed Original ResearchAltmetricConceptsTreatment-emergent adverse eventsRecurrent Clostridioides difficile infectionPreventing recurrent Clostridioides difficile infectionStandard-of-careSerious treatment-emergent adverse eventsTreatment successSustained clinical response ratesStandard-of-care antibioticsSustained clinical responseClinical response rateOpen-label studyTreatment success rateClostridioides difficile infectionMicrobiota-basedBaseline characteristic subgroupsObservational cohort studyFood and Drug AdministrationInflammatory bowel diseaseAntibiotic completionClinical responseSingle-doseEfficacy ratePrimary endpointSecondary endpointsImmunocompromised conditionsIntegrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, Khanna S, Berenson C, Wang E, Cohen S, Korman L, Lee C, Kelly C, Odio A, Cook P, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi D, Hasson B, McGovern B, von Moltke L, Pardi D. Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI. Infectious Diseases And Therapy 2024, 13: 2105-2121. PMID: 38941068, PMCID: PMC11416444, DOI: 10.1007/s40121-024-01007-z.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsPhase 3 trialRCDI rateAnalysis of treatment-emergent adverse eventsTreatment-related treatment-emergent adverse eventsStandard-of-care antibioticsHigh-risk patientsClostridioides difficile infectionPreventing rCDIRenal impairment/failureAbdominal painRecurrent CDIEfficacy analysisAdverse eventsTreatment-relatedPrevent recurrencePrevalent comorbiditiesRCDIWeeksAntibioticsPatientsComorbiditiesEfficacyPlaceboMicrobiomeLive biotherapeutic products: a capstone for prevention of recurrent Clostridiodes difficile infection
Sehgal K, Feuerstadt P. Live biotherapeutic products: a capstone for prevention of recurrent Clostridiodes difficile infection. Frontiers In Microbiomes 2024, 3: 1399440. DOI: 10.3389/frmbi.2024.1399440.Peer-Reviewed Original ResearchAltmetricConceptsClostridiodes difficile infectionLive biotherapeutic productsFecal microbiota transplantationStandard of careDifficile infectionFDA approvalHealthcare-acquired diarrheaReduction of recurrenceReducing CDI recurrencePrevention of recurrenceGut microbiotaGastrointestinal microbiotaCDI recurrenceAntimicrobial therapyMicrobiotaInfection onsetMicrobiota transplantationRecurrenceClinical practiceInfectionBiotherapeutic productsTherapyFDADeficiencyPrevention
News
News
Get In Touch
Events
Mar 202514Friday
Yale Only Paul Feuerstadt, MD, FACG, AGAF